AGC Biologics, Pyramid Pharma Services To Provide Integrated Manufacturing Solution

KUALA LUMPUR, July 1 (Bernama) -- AGC Biologics, a global biopharmaceutical contract development and manufacturing organisation (CDMO), has partnered with Pyramid Pharma Services to provide an integrated United States (US)-based manufacturing solution for drug developers.

The collaboration combines AGC Biologics' expertise in drug substance development and manufacturing with Pyramid's sterile fill-finish capabilities, providing developers with a fully integrated supply chain solution.

“We are always listening to our customers’ needs and responding with solutions that help them meet their goals. With this US-based fill-finish option, our Seattle site is well-positioned for developers that desire or even require end-to-end production in the US,” said AGC Biologics Chief Business Officer, Christoph Winterhalter.

Clients will gain access to comprehensive sterile fill-finish capabilities in the US, including liquid and lyophilised vials, pre-filled syringes and cartridges, as well as device assembly, labelling and secondary packaging services.

By combining AGC Biologics' expertise with Pyramid's experience in sterile drug product manufacturing, the partnership provides a seamless pathway from early development to commercial supply.

According to AGC Biologics in a statement, the integrated offering reduces project complexity and handoffs through centralised project management, enabling faster delivery of therapies to patients.

The new offering complements AGC Biologics' existing European fill-finish capabilities, providing clients with greater geographic flexibility and a robust US-based option to help navigate tariff exposure and strengthen supply chain security.

Pyramid Pharma Services brings nearly four decades of experience in sterile injectable drug product development, including 26 years in good manufacturing practice (GMP) manufacturing and over a decade of commercial supply, supported by a strong track record in quality, reliability and regulatory excellence.

-- BERNAMA